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Abstract: Significant improvements in the prognosis of Multiple Myeloma (MM) have 
recently observed in the era of novel agents. Induction treatment, including new agents 
followed by conditioning regimen and upfront autologous stem cell transplantation 
(ASCT), has been accepted as the standard treatment approach for newly diagnosed 
eligible MM patients. Despite novel agents, upfront ASCT is still superior to 
conventional chemotherapy alone. Previous studies revealed that the duration 
between ASCT and relapse had predicted overall survival (OS), and meantime, it was 
widely used to determine the potential benefit from a second ASCT. However, the 
majority of the data collected reflects the treatment modalities before novel agents. In 
this study, we aimed to investigate the impact of post-transplantation early relapse 
(ER) on survival in the era of novel agents. The results of 155 MM patients that 
underwent ASCT at our center between January 2010 and May 2018 were analyzed 
retrospectively. The median follow-up duration was 20 months in the ER group, 27 
months in the non-ER group, and 24 months in all patients. 33.3% of patients in the 
ER group and 71.4% of patients in the non-ER group were alive at the time of analysis. 
Median OS was 17 (95% CI, 12,8-21,2) months in the ER group and 33 (95% CI,18,9-
47,1) months in the non-ER group. We found a statistically significant relationship 
between the ER and the poor OS (p:<0.001). Our study reveals that in the era of novel 
agents, ER still related to poor survival. Therefore, comprehensive studies needed to 
develop new strategies for early relapsed patients. 
Keyword: Multiple myeloma; autologous stem cell transplantation; early relapse 
 
INTRODUCTION 
 Multiple myeloma (MM) is a plasma cell malignancy in which clonal plasma cells 
produce a monoclonal immunoglobulin. MM is the second most common hematologic 
malignancy. Median age at diagnosis is 70 years, and two-thirds of the patients are 
older than 65 years (Palumbo A., 2012 and Harousseau J.L., 2008). The advent of 
immunomodulatory drugs and proteasome inhibitors started a new era in the therapy 
of MM (Szalat R., 2019). Patients treated with these new agents have improved overall 
survival (OS) compared with patients who have never exposed to these agents (Kumar 
S.K., 2008). In the last five years, the Food and Drug Administration approved 
pomalidomide, carfilzomib, ixazomib, panobinostat, and two monoclonal antibodies 
daratumumab and elotuzumab (Szalat R., 2019). Induction treatment, including new 
Medical Laboratory Technology Journal  
   
 Available online at : http://ejurnal-analiskesehatan.web.id 
ISSN 2461-0879 
 




6 (2), 2020, 92-99 
P a g e  | 93 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
agents followed by conditioning regimen and upfront autologous stem cell 
transplantation (ASCT), has accepted as the standard treatment approach for newly 
diagnosed fit MM patients. Even in the era of novel agents upfront, ASCT is still 
superior to conventional chemotherapy alone (Mikhael J., 2019). Recently, the benefit 
of high-dose chemotherapy followed by ASCT has verified in the treatment 
approaches, including immunomodulatory drugs and proteasome inhibitors (Palumbo 
A., 2014; Gay F., 2015; Attal M., 2017; Gay F., 2017).  
 However, even with novel agents, some patients develop resistance over time 
and continue to experience recurrent relapses; therefore, long-term disease control 
cannot achieve (Martinelli G., 2000; Corradini P., 2003). The prognosis of MM patients 
is quite heterogeneous.  Therefore, it is very crucial to find out every prognostic factor 
to predict survival, and for patients who expected to have shorter OS, new treatment 
strategies should consider. Factors about the host and disease itself, such as the 
properties of the tumor, the microenvironment, age, and comorbidities, were shown to 
be the significant prognostic features (Kumar S.K., 2008; Brenner H., 2008; Kastritis 
E., 2009). The time until relapse seems to be an important prognostic factor, and early 
relapse (ER) could be indicating high-risk disease biology (Jimenez-Zepeda V.H., 
2015; Majithia N., 2016; Palumbo A., 2007).  The previous studies revealed that 
duration between ASCT and relapse had predicted the OS, and meantime it was 
widely used to determine the potential benefit from a second ASCT (Jimenez-Zepeda 
V.H., 2015; Kumar S., 2008; Michaelis L.C., 2013). However, the majority of the data 
collected reflects the treatment modalities before the novel agents, and the 
developments in the past decade, including the novel agents and improvements in the 
patient care of pre and post-transplantation period, should make it very likely that these 
predictions will change. In this study, we aimed to investigate the effects of post-
transplantation ER on survival in the era of new agents. 
 
MATERIALS AND METHOD 
 The results of 155 MM patients that underwent ASCT at Dr.Abdurrahman 
Yurtaslan Ankara Oncology Training and Research Hospital between January 2010 
and May 2018 were analyzed retrospectively. The ethics committee approved the 
study of our center (2019-09/399). The patients’ age, gender, myeloma subgroup, 
stages, number of chemotherapy lines and radiotherapy (RT) they received before 
ASCT, presence of renal failure, the dose of melphalan they received, quantity of 
infused CD34+ cell and the pre-ASCT response given in Table 1. 
 The patients that did not receive bortezomib in the induction regimen not 
included in the study. Tandem transplantation patients described as having the second 
ASCT within six months without any progression or relapse after the first ASCT not 
included in the study. The patients that underwent ASCT 12 months after diagnosis 
that have follow-up durations less than 100 days or die within the first 100 days post-
ASCT not included in the study. The most frequently used induction treatment 
consisted of bortezomib, cyclophosphamide, and dexamethasone. Elderly patients 
with comorbidities received bortezomib and dexamethasone regimen. The patients' 
stages at the time of diagnosis recorded with International Staging System (ISS), 
Revised International Staging System (R-ISS), Durie-Salmon Stages (DS), and 
treatment response evaluated according to the criteria of International Myeloma 
Working Group (Durie BG,2006). 
 
Table 1: Patients’ characteristics 
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ISS: International staging system, R-ISS: revised-international 
staging system, CR: complete response, VGPR: very good 






 Patient Population (n) 
Age (median) 56 (25-81) 
Gender  Females(n):57/ Males (n):98 
MM 
Subgroup 
Heavy Chain (n):  116 
Light Chain (n): 32 
Non-secretory (n): 3 
Not evaluated (n):4 
ISS 
ISS I(n):     40  
ISS II(n):    49 
ISS III(n):   41  
Not evaluated (n): 25 
R-ISS 
R-ISS I (n): 21 
R-ISS II (n): 60 
R-ISS III (n): 11 





Not evaluated (n): 5 
Pre-transplantation 
response  
CR(n):     58 
VGPR(n): 39  
PR(n):      41 
Stable(n): 10  
Refractory(n):3 
Not evaluated (n): 4 
Chemotherapy 
line(s) 
1 line (n):  50 
2 lines (n):  90 
3 lines (n):  9 
4 line (n):  2 











Infused CD34+ cell 
(median) 
4.62 x106 /kg (2.4-13.4) 
P a g e  | 95 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
109 patients among 155 patients mobilized with a total of 10 μg/kg 
subcutaneous granulocyte stimulating agent (G-CSF) in 2 divided doses (2×5 μg/kg). 
Sixteen patients had mobilization failure with G-CSF alone, and they mobilized with 
high-dose cyclophosphamide (4.000 mg/m2) and G-CSF combination. Three patients 
had mobilization failure with G-CSF alone and high-dose cyclophosphamide (4.000 
mg/m2) G-CSF combination, and they mobilized with plerixafor and G-CSF 
combination. Mobilization data of 27 patients could not reach from the records. While 
the patients ≥70 years or who have a serum creatinine level of ≥2 mg/dL received 140 
mg/m2 melphalan as the conditioning regimen, the remaining patients received 200 
mg/m2 melphalan. OS described the duration from the date of transplantation to the 
date of death or the latest follow-up date for the survivors. Progression-free survival 
(PFS) defined as the duration from the date of transplantation to the progress in 
disease, death, or date of latest follow-up for the progression-free patients. Transplant-
related mortality (TRM) was defined as the cumulative death within the first 100 days 
after allo-SCT without any evidence of disease progression. The engraftment definition 
for neutrophil defined as the first day when the absolute neutrophil count (ANC) was 
>500/mm3 or 1000/mm3 for three consecutive days without any support, and for 
thrombocytes it was defined as the first day when thrombocyte count was >20000/mm3 
for three consecutive days without any support (Rihn C, 2004). 
According to international uniform response criteria for multiple myeloma, ER 
defined as relapse within one year after the date of ASCT or progressive disease 
(Durie BG,2006). Patients divided into two groups: the patients with relapse within the 
first 12 months of post-ASCT and the patients with relapse after 12 months or the 
patients with no relapse until the latest follow-up. The relationships between OS and 
age, gender, MM subtype (heavy chain, light chain, nonsecretory), International 
Staging System (ISS), Revised International Staging System (R-ISS), Durie Salmon 
stages (DS), pre-ASCT chemotherapy, melphalan dose, response to the induction 
treatment, the duration between diagnosis and ASCT and the duration to the 
progression investigated.   
 
Statistical Methods 
 IBM SPSS Statistics (version 21) software used for statistical analysis. 
Descriptive statistics used to summarize the data. Categorical data expressed as a 
ratio and numerical data were expressed as median and mean ± standard deviation. 
Kaplan-Meier Survival analysis test used to evaluate overall survival and progression-
free survival. Factors influencing OS and PFS among the groups were analyzed 
employing a log-rank test. P<0.05 value was set as statistically significant. 
 
RESULTS AND DISCUSSION 
 155 patients that underwent ASCT within 12 months after diagnosis and 
received bortezomib in induction treatment included in the study and the data analyzed 
retrospectively. 27 (17.4%) patients had ER after ASCT, 128 (82.6%) patients had a 
late relapse (after 12 months) or observed in remission. The median follow-up duration 
was 20 months in the ER group, 27 months in the non-ER group, and 24 months in all 
patients. 33.3% of patients in the ER group and 71.4% of patients in the non-ER group 
were alive at the time of analysis. Median OS was 17 (95% CI, 12,8-21,2) months in 
the ER group and 33 (95% CI,18,9-47,1) months in the non-ER group. We observed 
a statistically significant relationship between the ER and the poor OS (p:<0.001).  
We did not find any statistically significant relationship between OS and gender, 
MM subtype, ISS, Durie Salmon stage, number of chemotherapy lines received, 
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melphalan dose, pre-ASCT response, and the duration between progression and 
ASCT. There was only a relationship between R-ISS and OS (p=0.033).  
Post-ASCT CR rate in ER group was 77.8%, 62.5% in the non-ER group; while 
VGPR rate was 3.7% in ER group,  10.2% in the non-ER group; PR rate was 3.7% in 
the ER group, 18.8% in the non-ER group; there was no statistically significant 
difference among the groups regarding the post-ASCT responses  (p: 0.095). 
Table 2: The Factors Impacting OS 
 
 PFS OS 
Gender 0.873 0.775 
MM subtype 0.229 0.215 
ISS 0.522 0.560 
R-ISS   0.339 0.033* 
Durie Salmon stage 0.824 0.973 
Chemotherapy line(s) received 0.252 0.707 
Melphalan dose 0.607 0.795 
Pre-transplantation response 0.066 0.846 
        PFS: progression-free survival, OS: overall survival,  
        ISS: international staging system,  
        R-ISS: revised-international staging system 
 
The duration between ASCT and relapse seems to be an important prognostic 
factor, and ER could be indicating high-risk disease biology (Jimenez-Zepeda V.H., 
2015; Majithia N., 2016; Palumbo A., 2007). Developments in the past decade, 
including the novel agents and improvements in the patient care of the pre and post-
transplantation period, may overcome the adverse impact of ER on prognosis. 
However, the majority of the data collected reflects the treatment modalities before the 
novel agents. The significance of ER on survival was first described by Kumar et al. in 
2008. Among 494 patients that treated with conventional therapy and ASCT, 24% had 
ER, and in the non-ER group, OS was 41.8 months; it was 10.8 months in the ER 
group (Kumar S., 2008). In a retrospective study, Venner et al. found out that exposure 
to new agents after relapse improved the survival of ER patients (Venner C.P., 2011).  
In the study conducted by Lee et al., including 257 patients that underwent 
novel agent-based treatment and ASCT, 13.6% of the patients had ER. While the 
median OS in the ER group was 17.8 months, the median OS in the non-ER group 
could not reach throughout the follow-up duration (p=0.0001) (Lee H., 2018). In the 
study conducted with 432 patients that underwent ASCT at Mayo Clinic, 94 (22%) of 
the patients had a relapse within 12 months after ASCT. While the median OS had 
been 23.9 months in the ER group, it was 82.2 months in the non-ER group. Among 
the 265 patients with relapse after the transplantation, the median OS was 7.8 months 
in the ER group and 39.6 months in the late relapse group (Kumar S., 2008).  In 
the study conducted by Ong et al. with 215 patients that underwent ASCT, they 
reported that the risk of ER decreased with the new agents compared to the 
conventional treatment (p=0.234) (Ong S.Y., 2016). In our study, while 27 (17.4%) 
patients had a relapse within the first 12 months of ASCT, 128 (82.6%) patients had a 
late relapse (after 12 months), or they observed in remission (non-ER group). The 
median survival was 17 (95% CI, 12,8-21,2) months in the ER group and 33 (95% 
CI,18,9-47,1) months in the non-ER group. We found a statistically significant 
relationship between the ER group and the non-ER group concerning OS (p:<0.001). 
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So, our study suggests that even in the era of new agents, ER is still a poor prognostic 
factor for OS. 
 In the study conducted by Lee et al., ≥ VGPR response rate was 51.4% in the 
ER group and 80.5% in the non-ER group (p: 0.001). The total response rate was 
35.6% in the ER group and 25.7% in the non-ER group (p: 0.003) (Lee H., 2018). In 
our study, the CR rate was 77.8% in ER  group,  62.5% in non-ER group, VGPR rate 
was 3.7% in ER group, it was 10.2% in the non-ER group;  PR rate was 3.7% in ER 
group, it was 18.8% in the non-ER group; we did not observe any statistically 
significant difference between 2 groups regarding post ASCT responses(p: 0.095). 
This suggests that ER is predictive for poor OS irrespective of post-transplant 
response. There were some limitations to this study. This was a retrospective analysis, 
and there was no information about complications of treatment. The superior side is 




 The studies in both conventional chemotherapy and novel agent’s era 
emphasize the significance of ER in MM patients. In the era of novel agents, the ER 
still related to poor survival. This supports that there is a group of patients with whom 
long term response could not maintain and whose prognoses continue to remain weak 
despite the improved results obtained with the inclusion of new treatments. Therefore, 
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